Cancer

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

12 months ago

CAN Community Health and Moffitt Cancer Center Unite in Red for World AIDS Day

TAMPA, FL / ACCESSWIRE / November 29, 2023 / CAN Community Health, in collaboration with Moffitt Cancer Center, proudly announces…

12 months ago

St. Joseph’s/Candler Fast Tracks Implementation of MEDITECH Expanse Ambulatory Across 100+ Providers

Expanse Oncology the next step toward creating a single, patient-centered EHRCANTON, Mass.--(BUSINESS WIRE)--St. Joseph’s/Candler Health System (Savannah, GA) has taken…

12 months ago

AstraZeneca advances scientific leadership in hematology at ASH 2023

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of…

12 months ago

Therma Bright Prepares FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA)

Company's DCA Solution Offers Robust Set of User and Medical Practitioner Features via an Android & iOS Mobile App and…

12 months ago

SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

Independent Data Monitoring Committee Scheduled to Meet This QuarterNEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group,…

12 months ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

12 months ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…

12 months ago

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

MINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for…

12 months ago